<DOC>
	<DOCNO>NCT01698320</DOCNO>
	<brief_summary>The purpose study evaluate safety Albuterol Spiromax® 52 week two dose period : ( 1 ) 12-week , double-blind , placebo-controlled QID dosing period follow ( 2 ) 40-week , open-label PRN dosing period , evaluate Albuterol Spiromax® device performance life device study .</brief_summary>
	<brief_title>Safety Study Albuterol Spiromax® Subjects With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Written inform consent HIPAA sign date subject write informed assent sign date subject and/or parent/caregiver/legal guardian conduct study related procedure . Males females asthma age 12 year old screening . Documented history persistent asthma current use MDI contain shortacting betaadrenergic agonist ( e.g . albuterol , levalbuterol , ) average least once/week 4weeks prior screening . The asthma diagnosis must consistent diagnosis asthma per National Asthma Education Prevention Program . If female , currently pregnant , breast feeding , attempt become pregnant ( 4 week screen visit throughout duration study ) , Nonchildbearing potential , define : ≥1 year postmenopausal Surgically sterile ( tubal ligation , bilateral oophorectomy , salpingectomy , hysterectomy ) Childbearing potential , negative serum pregnancy test , willing commit use consistent acceptable method birth control General good health opinion investigator indicate medical history , physical examination , laboratory test ( hematology , serum chemistry urinalysis ) assess either normal abnormal clinically significant ( NCS ) per principal investigator , well 12lead ECG interpret either `` Normal '' `` Abnormal NCS '' determine central cardiologist . Subjects must also free clinically significant , uncontrolled concomitant condition asthma could interfere study conduct , influence interpretation study observations/results , put subject increase risk trial . Capable understanding requirement , risk , benefit study participation , , judge investigator , compliant study requirement ( visit , recordkeeping , etc ) . Nonsmoker least one year prior screen visit maximum packyear ( PY ) smoke history 10 year . Able demonstrate proper inhaler technique study inhaler . Pregnancy , nursing , plan become pregnant donate gamete ( ova sperm ) vitro fertilization study period 30 day follow subject 's last study relate visit . Participation investigational drug trial within 30 day precede screen visit plan participation another investigational drug trial time trial . A known hypersensitivity albuterol excipients formulation . History severe milk protein allergy History upper low respiratory tract infection disorder ( include , limited bronchitis , pneumonia , acute chronic sinusitis , otitis medium , influenza , etc ) resolve least 1 week prior SV . History alcohol drug abuse within two year precede SV . Use protocol prohibit concomitant medication asthma ( oral β2adrenergic agonist ) protocol prohibit concomitant nonasthma medication include treatment β2adrenergic receptor antagonist nonselective βreceptor block agent βblocking antihypertensive product ( administer route ) , MAO inhibitor , and/or tricyclic antidepressant . ( Subject 's MDI shortacting βagonist rescue inhaler use start RunIn period study rescue inhaler provide . ) Inability unwillingness comply protocol requirement . History lifethreatening asthma [ define asthma episode require intubation and/or associate hypercapnea , respiratory arrest hypoxic seizure . ] Any asthma exacerbation within 3 month SV require oral systemic corticosteroid hospitalization asthma within 6 month SV . Note : An exacerbation asthma define worsen asthma require treatment rescue albuterol subject 's regular asthma maintenance therapy . This include require use systemic corticosteroid and/or emergency room visit hospitalization change subject 's regular asthma maintenance treatment . A subject need withdrawn study due asthma exacerbation unless hospitalization require unless principal investigator believe subject ' best interest withdraw study . Previous participation inhale Albuterol Spiromax® ( Teva ) study , exception ABSAS306 study . Study participation clinical investigator site employee and/or immediate relative . Study participation relate nonrelated individual live household , i.e . one subject per household may participate study . Any clinically significant endocrine , hematological , hepatic , renal , gastrointestinal , neurological , cardiac , metabolic , immunological , nonasthmatic acute chronic pulmonary condition ( include limit bronchitis , emphysema , active tuberculosis , bronchiectasis , cystic fibrosis ) , malignancy basal cell carcinoma . Significant define protocol condition , opinion investigator , would put safety subject risk participation , could affect safety analysis . Any medical psychological condition investigator 's opinion preclude enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>